8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study) | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Boerekamps A, Vanwolleghem T, Van Der Valk M, et al. 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). J Hepatol. 2019;70(3):554-557.

Publication Type:

Journal Article

Authors:

Boerekamps, Anne; Vanwolleghem, T; Van Der Valk, M.; et, al

Source:

J Hepatol, Volume 70, Issue 3, p.554-557 (2019)

Cited On:

Treatment-Naive Genotype 4 Without Cirrhosis

Export Citation:

RIS Format

Top